Singapore-based medical testing firm Mirxes joins Jiangsu Hengrui Pharmaceuticals in revitalised market’s listing surge.

Trading in the shares is expected to start on May 23. Read more at straitstimes.com. Read more at straitstimes.com.

SINGAPORE] Singapore biotech start-up Mirxes launched its initial public offering (IPO) in Hong Kong on Thursday (May 15) as ...

City’s largest share sale in four years shows Beijing’s determination to push China’s EV technologies worldwide, analysts say ...

Hong Kong is calling for robotaxi operator Pony AI . The $6 billion Chinese company is exploring an offering in the city just ...

Jiangsu Hengrui Pharmaceuticals is planning to raise as much as US$1.27 billion via an initial public offering in Hong Kong, joining a wave of Chinese companies seeking to tap the city's market.

China’s Zijin Mining Group (OTCPK:ZIJMF) (OTCPK:ZIJMY) has picked Citic Securities Co. and Morgan Stanley (MS) to lead the ...

(Reuters) -Chinese drug developer and producer Jiangsu Hengrui Pharmaceuticals is seeking to raise up to HK$9.89 billion ($1.27 billion) in a Hong Kong initial public offering, according to a ...

This digital payment services provider is likely to get a lift from China's initiatives to boost domestic consumption.

SINGAPORE] Companies have been flocking to file applications for initial public offerings (IPOs) in Hong Kong amid ...

Artificial intelligence-driven drug firm METiS Pharmaceuticals is considering an initial public offering in Hong Kong to ...

Chinese battery giant Contemporary Amperex Technology is planning to raise as much as US$4.0 billion in the year’s biggest ...